Researchers discovered that certain MMP-14 inhibitor peptides exhibit dramatically different metal-binding preferences depending on their structure. While most MMP inhibitors are designed to target zinc at the enzyme active site, one peptide (Inh4) with a poly-glycine tail showed exceptional affinity for copper instead—binding it over 1 million times more tightly than zinc. This finding is significant for peptide therapeutics like GHK-Cu because it demonstrates that peptide design choices (especially extended amino acid sequences) can unexpectedly redirect metal coordination, which matters in copper-rich tumor environments and could impact both therapeutic efficacy and safety of copper-containing peptide supplements.
For your business
Poly-glycine tails can shift peptide metal affinity strongly toward copper; relevant when considering GHK-Cu in copper-rich tumor environments.